Asahi Kasei Bioprocess, subsidiary of diversified Japanese technology company Asahi Kasei, will be featuring their MOTIV Buffer Management Technology at ACHEMA 2022 in Frankfurt this August.
![Asahi Kasei Bioprocess MOTIV™ Buffer Management Technology for Pharmaceutical Manufacturing[33] copy.png](https://pharmaceuticalmanufacturer.media/downloads/8952/download/Asahi%20Kasei%20Bioprocess%20MOTIV%E2%84%A2%20Buffer%20Management%20Technology%20for%20Pharmaceutical%20Manufacturing%5B33%5D%20copy.png?cb=6e26a1718903619a5c3ccaed220f0135&w={width}&h={height} "Asahi Kasei Bioprocess MOTIV™ Buffer Management Technology for Pharmaceutical Manufacturing[33] copy.png")
Key highlights:
- Asahi Kasei Bioprocess will showcase their MOTIV Buffer Management Technology for pharmaceutical manufacturing at Achema 2022.
- MOTIV keeps pharmaceutical production moving efficiently and precisely, so that medicine can be produced in larger quantities, and can get to patients sooner and safer.
- It is automated by the integrated OCELOT System Control software, which makes the whole process repeatable and also helps to reduce waste created in the development process.
Using built-in automation software, MOTIV keeps pharmaceutical production moving efficiently and precisely, so that medicine can be produced in larger quantities, be made more available globally and can get to patients sooner and safer.
Winner of “Best in Show” at Interphex in 2017, “Technology of the Decade” from Bioprocess international in 2012 and originator of the concept for inline buffer formulation (IBF), Asahi Kasei Bioprocess has been constantly pushing the boundaries in the field of buffer formulation systems.
Buffers are used for the vast majority of processes in pharmaceutical development, which has traditionally required storage in extremely large tank farms to be utilised as necessary. MOTIV can blend buffers from concentrates in small, single-use bags and is controlled with sensors to maintain and assure precision. It is also able to blend buffers to exact specifications as needed during a downstream development process and can handle a wide variety of buffer formulations.
In addition, it is automated by the integrated OCELOT System Control software, a technology that integrates and/or interfaces with plant-wide control systems in a universally compatible format, allowing for far-reaching data collection and analysis. OCELOT makes the whole process repeatable and also helps to reduce waste created in the development process, so it is a more sustainable means of pharmaceutical manufacturing.
“We have been working to ‘standardise’ system designs as much as we can, to make them more readily available with shorter lead times; but are also very capable at building custom systems to meet the specific needs of customers,” says Chris Rombach, vice president of Sales and Marketing at Asahi Kasei Bioprocess America.
“One of our strengths is not only having an innovative product, but also an extensive family of MOTIV systems to choose from. Buffer is the lifeblood of pharma manufacturing and with the R&D opportunities of being a part of the Asahi Kasei Group we have been able to develop MOTIV to be the most reliable and efficient IBF technology in the market today. Not to mention, Operation Warp Speed helped push capacity to expand globally and billions of dollars are being invested by manufacturers to ramp up production as quickly as possible. This drives a new sense of value for systems like our MOTIV family that can streamline processes.”
Asahi Kasei Bioprocess will display its solutions from 22-26 August 2022 at ACHEMA, the leading international event for the process industry, in Frankfurt, Germany.